Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Key Stats

• Today's Range: $2.98 to $3.18
• 50-Day Range: $2.32 to $3.62
• 52-Week Range: $2.20 to $5.58
• Volume: 8,718 shs
• Average Volume: 16,279 shs
• Market Capitalization: $81.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Strong Buy

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

Eupraxia Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 640th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Eupraxia Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.67, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eupraxia Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eupraxia Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eupraxia Pharmaceuticals is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eupraxia Pharmaceuticals is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eupraxia Pharmaceuticals has a P/B Ratio of 99.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.49% of the float of Eupraxia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in Eupraxia Pharmaceuticals has recently decreased by 1.94%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eupraxia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.49% of the float of Eupraxia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in Eupraxia Pharmaceuticals has recently decreased by 1.94%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Eupraxia Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for EPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.

EPRX Stock Analysis - Frequently Asked Questions

How have EPRX shares performed this year?

Eupraxia Pharmaceuticals' stock was trading at $2.72 at the start of the year. Since then, EPRX stock has increased by 9.6% and is now trading at $2.98.
View the best growth stocks for 2024 here.

How do I buy shares of Eupraxia Pharmaceuticals?

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Eupraxia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Companies (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

• Today: 12/19/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPRX
• Previous Symbol: NASDAQ:EPRX
• CUSIP: N/A
• CIK: 1581178
• Web: www.eupraxiapharma.com
• Phone: 250-590-3968
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +202.0%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-28,220,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -219.64%
• Return on Assets: -96.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.17
• Quick Ratio: 4.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 99.33

Miscellaneous

• Outstanding Shares: 27,282,000
• Free Float: N/A
• Market Cap: $81.30 million
• Optionable: N/A
• Beta: N/A